Gilead Sciences Inc (GILD) 80.46 $GILD What Awaits MNK &

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 6:08 AM

Gilead Sciences Inc (GILD) 80.46 $GILD

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 67.37 (+0.03), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), PFE: 37.31 (+0.42), SGNT: 21.68 (-0.01), ABBV: 66.94 (+0.71), PRTA: 56.66 (+1.61), NVS: 83.07 (-0.19)

Gilead Sciences (GILD) Approaches New Downside Target of $79.92
Comtex SmarTrend(R) - Fri Jul 29, 9:09AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $81.28 today and has reached the first level of support at $80.58. Should the shares continue to fall, the support pivots of $79.92 and $78.56 will be of interest.
GILD: 80.46 (+0.99)

What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), NVLS: 4.76 (+0.08), CYTR: 0.60 (-0.05), CEMP: 18.50 (+0.53), ACUR: 1.91 (-0.03), NVS: 83.07 (-0.19)

Research Reports for Facebook, DuPont, Gilead & Others
Sheraz Mian - Zacks Investment Research - Thu Jul 28, 1:23PM CDT
Research Reports for Facebook, DuPont, Gilead & Others
GS: 158.18 (-0.63), GILD: 80.46 (+0.99), FB: 124.31 (+0.37), BCE: 48.02 (+0.13), ADI: 63.98 (+0.15), DD: 69.35 (+0.18), M: 35.32 (-0.51)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Express Scripts (ESRX) Posts In-Line Earnings, Lags Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 10:19AM CDT
Pharmacy benefit manager Express Scripts Holding Company (ESRX) posted second-quarter 2016 earnings per share (excluding special items) of $1.57, in line with the Zacks Consensus Estimate.
ANTM: 127.61 (-3.73), JNJ: 125.40 (+0.17), ESRX: 76.17 (+0.10), GILD: 80.46 (+0.99)

Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)

Gilead Sciences Inc A Great Opportunity Post Q2 Earnings
Jack Foley - Amigobulls - Wed Jul 27, 6:47AM CDT
Gilead Sciences Inc (NASDAQ:GILD) shares tumbled after the company reported its Q2 earnings. Here's why this could be a great opportunity for investors.
GILD: 80.46 (+0.99)

Downgrade Alert for Gilead Sciences (GILD)
Comtex SmarTrend(R) - Wed Jul 27, 4:11AM CDT
Gilead Sciences (NASDAQ:GILD) was downgraded from Buy to Hold at Needham today. The stock closed yesterday at $81.05 on volume of 47.3 million shares, above average daily volume of 11.2 million. There is potential upside of 55.2% for shares of Gilead Sciences based on a current price of $81.05 and an average consensus analyst price target of $125.80. The stock should find initial resistance at its 50-day moving average (MA) of $92.98 and further resistance at its 200-day MA of $100.22.
GILD: 80.46 (+0.99)

After GILD Earnings, Which Biomed Stock is Best Right Now?
Ryan McQueeney - Zacks Investment Research - Tue Jul 26, 3:55PM CDT
For many investors, Gilead is the go-to stock in the biomed industry. However, with revenues looking sluggish this year, these three Zacks Rank #1 (Strong Buy) stocks might end up being a better bet.
INVA: 13.04 (+0.17), GILD: 80.46 (+0.99), ANIP: 61.06 (+0.46)

Gilead Sciences and McDonald's slip; Texas Instruments rises
AP - Tue Jul 26, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
CNC: 69.44 (-1.11), CE: 62.88 (-0.54), GILD: 80.46 (+0.99), TXN: 69.88 (+0.13), LVS: 50.24 (-0.41), SIRI: 4.34 (-0.05)

SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 8.45% Loss
Comtex SmarTrend(R) - Tue Jul 26, 11:45AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $81.02 to a high of $84.15. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $86.28 on volume of 29.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 80.46 (+0.99)

Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 8.45%
Comtex SmarTrend(R) - Tue Jul 26, 11:43AM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $81.02 to a high of $84.15. Yesterday, the shares fell 8.4%, which took the trading range below the 3-day low of $86.28 on volume of 29.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 80.46 (+0.99)

Gilead (GILD) Beats on Q2 Earnings, Cuts 2016 Sales View
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:07AM CDT
Gilead Sciences' (GILD) second-quarter 2016 earnings beat the Zacks Consensus Estimate by a penny while revenues missed estimates; product sales outlook is lowered.
INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), GILD: 80.46 (+0.99), NKTR: 17.76 (+0.47)

The Zacks Analyst Blog Highlights: Texas Instruments, Gilead Sciences and Las Vegas Sands
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: Texas Instruments, Gilead Sciences and Las Vegas Sands
GILD: 80.46 (+0.99), TXN: 69.88 (+0.13), LVS: 50.24 (-0.41)

Express Scripts (ESRX) Tops Q2 Earnings, Lags Revenues
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 7:55AM CDT
Pharmacy benefit manager Express Scripts Holding Company (ESRX) posted second-quarter 2016 earnings per share (excluding special items) of $1.57, in line with the Zacks Consensus Estimate.
ANTM: 127.61 (-3.73), JNJ: 125.40 (+0.17), ESRX: 76.17 (+0.10), GILD: 80.46 (+0.99)

Roche (RHHBY) Misses on Q2 Revenues, New Launches in Focus
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 5:32PM CDT
Roche Holding (RHHBY) reported sales of $12.1 billion in the second quarter of 2016, missing the Zacks Consensus Estimate of $12.9 billion.
JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ABBV: 66.94 (+0.71)

Q2 Earnings After the Bell Monday: TXN, GILD, LVS
Mark Vickery - Zacks Investment Research - Mon Jul 25, 4:49PM CDT
Texas Instruments, Gilead Sciences and Las Vegas Sands are among the smorgasbord of Q2 earnings reports today.
GILD: 80.46 (+0.99), TXN: 69.88 (+0.13), LVS: 50.24 (-0.41)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Schneider Electric Pushes Water Management Tech at WEFTEC

Looks like Schneider Electric is diving headfirst into the choppy waters of utility management with its latest tech showcase at WEFTEC 2026. And trust me, the timing couldn't be more spot-on. With North America's water and wastewater systems groaning under the weight of aging infrastructure and cybersecurity threats, it’s about time someone brought something fresh to...

PVOLVE Expands Reach with New Franchises in 2026

The PVOLVE Fitness Craze Picks Up Momentum Seriously, if you hadn’t heard of PVOLVE before, now might be the time to get your ears in tune—and maybe consider hitting up one of their studios. They’ve been on an expansion tear, with franchise deals popping up like daisies in Washington and Wisconsin. It's the two new spots in Tacoma and Brookfield that are grabbing...

RiskScout Rides High on Funding, Tackles Financial Crime

A Fresh Injection to Combat Financial Crime Capital's flowing into RiskScout's coffers thanks to a new funding round, and it's not just about cash—it’s about gearing up for a battle against financial crime. The round was led by LiveOak Ventures, who aren't new to the block, alongside other players like Castle Creek Launchpad and Alloy Labs. After tripling their...

Appy Pie Secures Patent for AI Driven App Building

A New Dawn in App Creation You ever think about a world where creating an app is as straightforward as chatting with an old buddy? Well, that future's knocking at the door, courtesy of Appy Pie. They're ruffling feathers with a shiny new U.S. patent promising just that—apps whipped into shape by a bit of chitchat with their AI-powered platform. It's got folks scratching...

Derek Pesta Shines: Forbes Top Wealth Advisors 2026

An Unwavering Dedication to Clients Every once in a while, the industry tips its hat to someone who truly knows what they're doing. Derek Pesta, head honcho at Pesta & Pesta Wealth Management, has landed on the 2026 Forbes Top Next-Gen Wealth Advisors Best-in-State list. It’s not just a pat on the back; it's a solid nod to the way he runs his game. You know it’s big...

LifeLabs' AI Program: A Manager's New Toolbox

Management In the Age of AI: New Frontiers Gone are the days when a simple software update meant staying competitive. We're in a new era, folks—one where AI isn't just a handy tool—it's reshaping entire industries. But here's the kicker: all the fancy tech in the world won't do squat without savvy managers who know how to drive adoption. Yup, that's the naked truth,...

Craig Hospital Expands: A Milestone for Rehab Care

A Bold Step Forward in Neurorehabilitation Over a September sky in Englewood, Colorado, a ceremonial beam rose, marking a major milestone for Craig Hospital. It's not just steel and concrete; it's hope and progress for many who've found themselves at the mercy of neurological injuries. Celebrating the 'topping out' of their expanded campus, Craig's latest step forward...

Primrose Schools App: A Bold Step for Digital Literacy

Primrose Schools Delivers a New Era in Child Education Sitting at a crossroads between the tactile charm of hands-on learning and the inevitable march of digital literacy, Primrose Schools has unveiled something that might just rock the boat in early education: their new Balanced Learning® App. This move by Primrose comes at a crucial time when many parents are...

Multiply's AI Agent Tackles $126K Google Ads Waste

AI Steps In Where Marketers Hit a Wall Picture this: marketers drowning in search terms flying at them faster than they can blink. Multiply's new AI-powered Ad Spend Recovery Agent steps in, claiming to save an eye-watering $126,000 per year by cutting Google Ads waste. Talk about having a hawk-eyed auditor sifting through your accounts. Shaking Up Traditional Automation...

Books-A-Million's Impactful 2026 Coffee for Troops Campaign

A Modest Cup, A Massive Impact Ever wonder how something as simple as a bag of coffee could bridge the gap between a service member far from home and their loved ones? Well, Books-A-Million has got that figured out, and they're taking it to another level with their 2026 Coffee for the Troops campaign. This isn't just about a hot brew; it's about stirring up a storm of...